{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T02:51:51Z","timestamp":1786243911824,"version":"build-2736575974"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T00:00:00Z","timestamp":1686096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T00:00:00Z","timestamp":1686096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s40262-023-01252-4","type":"journal-article","created":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T14:01:59Z","timestamp":1686146519000},"page":"1081-1091","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Population Pharmacokinetics of Total Rabbit Anti-thymocyte Globulin in Non-obese Adult Patients Undergoing Hematopoietic Cell Transplantation for Hematologic Malignancy"],"prefix":"10.1007","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8296-6412","authenticated-orcid":false,"given":"Takuto","family":"Takahashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Teramoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kana","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mutaz M.","family":"Jaber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroya","family":"Tamaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Ikegame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Yoshihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuji","family":"Kaida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,7]]},"reference":[{"issue":"6","key":"1252_CR1","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1038\/s41409-020-0792-x","volume":"55","author":"F Bonifazi","year":"2020","unstructured":"Bonifazi F, Rubio MT, Bacigalupo A, Boelens JJ, Finke J, Greinix H, et\u00a0al. Rabbit ATG\/ATLG in preventing graft-versus-host disease after allogeneic stem cell transplantation: consensus-based recommendations by an international expert panel. Bone Marrow Transplant. 2020;55(6):1093\u2013102.","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"1252_CR2","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1080\/10428194.2016.1266624","volume":"58","author":"Y Arai","year":"2017","unstructured":"Arai Y, Jo T, Matsui H, Kondo T, Takaori-Kondo A. Efficacy of antithymocyte globulin for allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis. Leuk Lymphoma. 2017;58(8):1840\u20138.","journal-title":"Leuk Lymphoma"},{"key":"1252_CR3","doi-asserted-by":"publisher","first-page":"828094","DOI":"10.3389\/fphar.2022.828094","volume":"13","author":"JI Meesters-Ensing","year":"2022","unstructured":"Meesters-Ensing JI, Admiraal R, Ebskamp L, Lacna A, Boelens JJ, Lindemans CA, et\u00a0al. Therapeutic drug monitoring of anti-thymocyte globulin in allogeneic stem cell transplantation: proof of concept. Front Pharmacol. 2022;13:828094.","journal-title":"Front Pharmacol"},{"issue":"1","key":"1252_CR4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0966-3274(01)00048-X","volume":"9","author":"JF Regan","year":"2001","unstructured":"Regan JF, Lyonnais C, Campbell K, Smith LV, Buelow R, Group USTM-CS. Total and active Thymoglobulin levels: effects of dose and sensitization on serum concentrations. Transpl Immunol. 2001;9(1):29\u201336.","journal-title":"Transpl Immunol"},{"issue":"2","key":"1252_CR5","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.bbmt.2008.11.027","volume":"15","author":"SK Call","year":"2009","unstructured":"Call SK, Kasow KA, Barfield R, Madden R, Leung W, Horwitz E, et\u00a0al. Total and active rabbit antithymocyte globulin (rATG;Thymoglobulin) pharmacokinetics in pediatric patients undergoing unrelated donor bone marrow transplantation. Biol Blood Marrow Transplant. 2009;15(2):274\u20138.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"1252_CR6","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/S1083-8791(03)00127-7","volume":"9","author":"EK Waller","year":"2003","unstructured":"Waller EK, Langston AA, Lonial S, Cherry J, Somani J, Allen AJ, et\u00a0al. Pharmacokinetics and pharmacodynamics of anti-thymocyte globulin in recipients of partially HLA-matched blood hematopoietic progenitor cell transplantation. Biol Blood Marrow Transplant. 2003;9(7):460\u201371.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"1252_CR7","doi-asserted-by":"publisher","first-page":"e183","DOI":"10.1016\/S2352-3026(17)30029-7","volume":"4","author":"R Admiraal","year":"2017","unstructured":"Admiraal R, Nierkens S, de Witte MA, Petersen EJ, Fleurke GJ, Verrest L, et\u00a0al. Association between anti-thymocyte globulin exposure and survival outcomes in adult unrelated haemopoietic cell transplantation: a multicentre, retrospective, pharmacodynamic cohort analysis. Lancet Haematol. 2017;4(4):e183\u201391.","journal-title":"Lancet Haematol."},{"issue":"4","key":"1252_CR8","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s40262-014-0214-6","volume":"54","author":"R Admiraal","year":"2015","unstructured":"Admiraal R, van Kesteren C, Jol-van der Zijde CM, van Tol MJ, Bartelink IH, Bredius RG, et\u00a0al. Population pharmacokinetic modeling of Thymoglobulin(\u00ae) in children receiving allogeneic-hematopoietic cell transplantation: towards improved survival through individualized dosing. Clin Pharmacokinet. 2015;54(4):435\u201346.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"1252_CR9","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1016\/j.bbmt.2019.12.577","volume":"26","author":"R Admiraal","year":"2020","unstructured":"Admiraal R, Nierkens S, Bredius R, Bierings M, van Vliet I, Yurda ML, et\u00a0al. Prospective open-label phase II trial of individualized anti-thymocyte globulin for improved T-cell reconstitution after pediatric allogeneic hematopoietic cell transplantation: the parachute-study. Biol Blood Marrow Transplant. 2020;26(3):S33\u20134.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"1252_CR10","doi-asserted-by":"publisher","first-page":"e111","DOI":"10.1016\/S2352-3026(21)00375-6","volume":"9","author":"R Admiraal","year":"2022","unstructured":"Admiraal R, Nierkens S, Bierings MB, Bredius RGM, van Vliet I, Jiang Y, et\u00a0al. Individualised dosing of anti-thymocyte globulin in paediatric unrelated allogeneic haematopoietic stem-cell transplantation (PARACHUTE): a single-arm, phase 2 clinical trial. Lancet Haematol. 2022;9(2):e111\u201320.","journal-title":"Lancet Haematol."},{"issue":"5","key":"1252_CR11","doi-asserted-by":"publisher","first-page":"e194","DOI":"10.1016\/S2352-3026(15)00045-9","volume":"2","author":"R Admiraal","year":"2015","unstructured":"Admiraal R, van Kesteren C, Jol-van der Zijde CM, Lankester AC, Bierings MB, Egberts TC, et\u00a0al. Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis. Lancet Haematol. 2015;2(5):e194-203.","journal-title":"Lancet Haematol."},{"issue":"2","key":"1252_CR12","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1007\/s12185-022-03342-8","volume":"116","author":"M Teramoto","year":"2022","unstructured":"Teramoto M, Maruyama S, Tamaki H, Kaida K, Mayumi A, Fukunaga K, et\u00a0al. Association between the pharmacokinetics of rabbit anti-thymocyte globulin and acute graft-versus-host disease in patients who received haploidentical hematopoietic stem cell transplantation. Int J Hematol. 2022;116(2):248\u201357.","journal-title":"Int J Hematol"},{"key":"1252_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.826004","volume":"13","author":"M van der Stoep","year":"2022","unstructured":"van der Stoep M, Oostenbrink LVE, Bredius RGM, Moes D, Guchelaar HJ, Zwaveling J, et\u00a0al. Therapeutic drug monitoring of conditioning agents in pediatric allogeneic stem cell transplantation; where do we stand? Front Pharmacol. 2022;13: 826004.","journal-title":"Front Pharmacol"},{"issue":"8","key":"1252_CR14","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.bbmt.2015.04.012","volume":"21","author":"K Ikegame","year":"2015","unstructured":"Ikegame K, Yoshida T, Yoshihara S, Daimon T, Shimizu H, Maeda Y, et\u00a0al. Unmanipulated haploidentical reduced-intensity stem cell transplantation using fludarabine, busulfan, low-dose antithymocyte globulin, and steroids for patients in non-complete remission or at high risk of relapse: a prospective multicenter phase I\/II study in Japan. Biol Blood Marrow Transplant. 2015;21(8):1495\u2013505.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"1252_CR15","first-page":"650","volume":"8","author":"BJ Devine","year":"1974","unstructured":"Devine BJ. Gentamicin therapy. Drug Intell Clin Pharm. 1974;8(11):650\u20135.","journal-title":"Drug Intell Clin Pharm"},{"issue":"6","key":"1252_CR16","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s10928-016-9487-8","volume":"43","author":"AG Dosne","year":"2016","unstructured":"Dosne AG, Bergstrand M, Harling K, Karlsson MO. Improving the estimation of parameter uncertainty distributions in nonlinear mixed effects models using sampling importance resampling. J Pharmacokinet Pharmacodyn. 2016;43(6):583\u201396.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"2","key":"1252_CR17","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13(2):143\u201351.","journal-title":"AAPS J"},{"issue":"9","key":"1252_CR18","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1023\/A:1011970125687","volume":"15","author":"EN Jonsson","year":"1998","unstructured":"Jonsson EN, Karlsson MO. Automated covariate model building within NONMEM. Pharm Res. 1998;15(9):1463\u20138.","journal-title":"Pharm Res"},{"issue":"9","key":"1252_CR19","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/psp4.12224","volume":"6","author":"JT Ryman","year":"2017","unstructured":"Ryman JT, Meibohm B. Pharmacokinetics of monoclonal antibodies. CPT Pharmacometrics Syst Pharmacol. 2017;6(9):576\u201388.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"6","key":"1252_CR20","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1023\/A:1014414520282","volume":"28","author":"DE Mager","year":"2001","unstructured":"Mager DE, Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn. 2001;28(6):507\u201332.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"10","key":"1252_CR21","doi-asserted-by":"publisher","first-page":"633","DOI":"10.2165\/11535960-000000000-00000","volume":"49","author":"NL Dirks","year":"2010","unstructured":"Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49(10):633\u201359.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"1252_CR22","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s00280-020-04160-7","volume":"86","author":"SV Bhoopalan","year":"2020","unstructured":"Bhoopalan SV, Cross SJ, Panetta JC, Triplett BM. Pharmacokinetics of alemtuzumab in pediatric patients undergoing ex vivo T-cell-depleted haploidentical hematopoietic cell transplantation. Cancer Chemother Pharmacol. 2020;86(6):711\u20137.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"12","key":"1252_CR23","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1007\/s40262-019-00782-0","volume":"58","author":"R Admiraal","year":"2019","unstructured":"Admiraal R, Jol-van der Zijde CM, Furtado Silva JM, Knibbe CAJ, Lankester AC, Boelens JJ, et\u00a0al. Population pharmacokinetics of alemtuzumab (Campath) in pediatric hematopoietic cell transplantation: towards individualized dosing to improve outcome. Clin Pharmacokinet. 2019;58(12):1609\u201320.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"1252_CR24","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1111\/j.0894-0959.2004.17603.x","volume":"17","author":"BR Don","year":"2004","unstructured":"Don BR, Kaysen G. Serum albumin: relationship to inflammation and nutrition. Semin Dial. 2004;17(6):432\u20137.","journal-title":"Semin Dial"},{"issue":"4","key":"1252_CR25","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.humimm.2005.01.029","volume":"66","author":"F Jin","year":"2005","unstructured":"Jin F, Balthasar JP. Mechanisms of intravenous immunoglobulin action in immune thrombocytopenic purpura. Hum Immunol. 2005;66(4):403\u201310.","journal-title":"Hum Immunol"},{"issue":"4","key":"1252_CR26","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1172\/JCI106279","volume":"49","author":"A Morell","year":"1970","unstructured":"Morell A, Terry WD, Waldmann TA. Metabolic properties of IgG subclasses in man. J Clin Invest. 1970;49(4):673\u201380.","journal-title":"J Clin Invest"},{"key":"1252_CR27","doi-asserted-by":"publisher","first-page":"507","DOI":"10.3389\/fimmu.2016.00507","volume":"7","author":"J Ogonek","year":"2016","unstructured":"Ogonek J, KraljJuric M, Ghimire S, Varanasi PR, Holler E, Greinix H, et\u00a0al. Immune reconstitution after allogeneic hematopoietic stem cell transplantation. Front Immunol. 2016;7:507.","journal-title":"Front Immunol"},{"issue":"22","key":"1252_CR28","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMra1609337","volume":"377","author":"R Zeiser","year":"2017","unstructured":"Zeiser R, Blazar BR. Acute graft-versus-host disease\u2014biologic process, prevention, and therapy. N Engl J Med. 2017;377(22):2167\u201379.","journal-title":"N Engl J Med"},{"issue":"7","key":"1252_CR29","first-page":"931","volume":"90","author":"M Remberger","year":"2005","unstructured":"Remberger M, Sundberg B. Rabbit-immunoglobulin G levels in patients receiving Thymoglobulin as part of conditioning before unrelated donor stem cell transplantation. Haematologica. 2005;90(7):931\u20138.","journal-title":"Haematologica"},{"issue":"9","key":"1252_CR30","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1080\/17425255.2017.1360277","volume":"13","author":"AL Myers","year":"2017","unstructured":"Myers AL, Kawedia JD, Champlin RE, Kramer MA, Nieto Y, Ghose R, et\u00a0al. Clarifying busulfan metabolism and drug interactions to support new therapeutic drug monitoring strategies: a comprehensive review. Expert Opin Drug Metab Toxicol. 2017;13(9):901\u201323.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"11","key":"1252_CR31","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/j.bbmt.2016.07.013","volume":"22","author":"J Palmer","year":"2016","unstructured":"Palmer J, McCune JS, Perales MA, Marks D, Bubalo J, Mohty M, et\u00a0al. Personalizing busulfan-based conditioning: considerations from the American Society for blood and marrow transplantation practice guidelines committee. Biol Blood Marrow Transplant. 2016;22(11):1915\u201325.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"1252_CR32","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1038\/s41409-021-01460-1","volume":"56","author":"DE Arnold","year":"2021","unstructured":"Arnold DE, Emoto C, Fukuda T, Dong M, Vinks AA, Lane A, et\u00a0al. A prospective pilot study of a novel alemtuzumab target concentration intervention strategy. Bone Marrow Transplant. 2021;56(12):3029\u201331.","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"1252_CR33","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1182\/blood-2015-07-659672","volume":"127","author":"RA Marsh","year":"2016","unstructured":"Marsh RA, Lane A, Mehta PA, Neumeier L, Jodele S, Davies SM, et\u00a0al. Alemtuzumab levels impact acute GVHD, mixed chimerism, and lymphocyte recovery following alemtuzumab, fludarabine, and melphalan RIC HCT. Blood. 2016;127(4):503\u201312.","journal-title":"Blood"},{"issue":"7","key":"1252_CR34","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.bbmt.2007.03.012","volume":"13","author":"JS McCune","year":"2007","unstructured":"McCune JS, Batchelder A, Deeg HJ, Gooley T, Cole S, Phillips B, et\u00a0al. Cyclophosphamide following targeted oral busulfan as conditioning for hematopoietic cell transplantation: pharmacokinetics, liver toxicity, and mortality. Biol Blood Marrow Transplant. 2007;13(7):853\u201362.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"1252_CR35","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1182\/blood-2002-06-1860","volume":"101","author":"GB McDonald","year":"2003","unstructured":"McDonald GB, Slattery JT, Bouvier ME, Ren S, Batchelder AL, Kalhorn TF, et\u00a0al. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood. 2003;101(5):2043\u20138.","journal-title":"Blood"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-023-01252-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-023-01252-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-023-01252-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,29]],"date-time":"2023-07-29T18:06:36Z","timestamp":1690653996000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-023-01252-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,7]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["1252"],"URL":"https:\/\/doi.org\/10.1007\/s40262-023-01252-4","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,7]]},"assertion":[{"value":"10 April 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The datasets generated and\/or analyzed during the current study are available from the corresponding author on reasonable request after an approval from the study committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Conceptualization: TT, MT; methodology, computational analysis, writing\u2014original draft preparation: TT; bioanalysis: KM; review of computational analysis: MJ; clinical sample acquisition: MT, HT, KI, SY, KK; data curation: MT; writing\u2014review and editing: all authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors have no competing interests associated with this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The present study was approved by the institutional review board at the Hyogo Medical University","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Patients and\/or their legal guardians provided written consent to participate in the present study.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Patients and\/or their legal guardians provided written consent for publication of the present study.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The code generated during the current study is available from the corresponding author on reasonable request after approval from the study committee.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}